What happens when we stop looking at one product, one trial, or one reimbursement argument—and zoom out?
Our newly published systematic review and meta-analysis in the International Wound Journal does just that. George Theodorakopoulos and I examined randomized evidence for placental-derived cellular, acellular, and matrix-like products (CAMPs) used as adjuncts to standard care for diabetic foot ulcers, focusing on one clinically meaningful endpoint: complete wound closure at 12 weeks.
The headline
Across 9 standard-care-controlled randomized comparisons including 944 participants, complete closure occurred in 59.0% of product-treated wounds versus 35.8% of controls. The pooled relative risk was 1.70 (95% CI 1.31–2.20).
That is a meaningful signal. But the more interesting message may be the caveat: the prediction interval crossed the null. In other words, the average benefit is real, but it should not be assumed that every product, every patient, or every clinical setting will reproduce that average effect.
That distinction matters. A meta-analysis is a telescope, not a stamp of approval. It helps us see the constellation—but individual stars still differ.
How this fits with the previous work
This paper is best read as part of a longer arc of evidence rather than in isolation.
- Our earlier work with William Tettelbach and colleagues emphasized that advanced products do not substitute for good wound-bed preparation. The blog post “The influence of debridement on diabetic foot ulcers” highlighted the relationship between adequate debridement and outcomes when placental-derived allografts are used.
- We also explored the health-economic and utilization side in “Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment”, including signals around hospitalization, readmission, emergency department use, and amputation.
- More recently, the policy conversation has become unavoidable. We summarized our concerns around proposed coverage policy in “A Critical Review of Proposed Draft CAMPs LCDs: Aligning Policy with Evidence-Based Medicine” and later revisited the balance between access, cost, and innovation in “Balancing Costs, Access, and Innovation in Wound Healing.”
Taken together, these studies tell a fairly coherent story: advanced wound products can help, but they work inside a system. That system includes perfusion, offloading, infection control, debridement, patient selection, product selection, and the discipline to measure outcomes consistently.
The part I find most important
The new analysis deliberately anchored the evidence to one time point—12 weeks—and one hard outcome—complete closure. That may sound like a methodological detail, but it is exactly the kind of discipline that can make evidence more useful at the bedside and in policy.
When we mix 4-week, 6-week, 12-week, and 16-week outcomes—or partial area reduction with complete closure—we risk comparing apples, oranges, and occasionally fruit salad. A cleaner endpoint gives clinicians, payers, and patients a more interpretable signal.
The result is encouraging, but not indiscriminate: placental-derived CAMPs appear to improve 12-week healing on average, with moderate-certainty evidence, while heterogeneity reminds us that evidence should remain product-specific and context-specific.
Where this should take us next
The next generation of work should move beyond asking simply, “Does this category work?” We should be asking:
- Which products work best for which wounds?
- What clinical phenotype predicts response?
- How much of the apparent treatment effect depends on the quality of standard care?
- Are wounds still closed at 6 or 12 months?
- Do these therapies reduce hospitalization, infection, amputation, and total cost—not merely accelerate closure?
That is the shift from product evidence to precision wound care.
Paper: Theodorakopoulos G, Armstrong DG. Cellular, Acellular, and Matrix-Like Placental Products for Diabetic Foot Ulcers: A 12-Week Randomised-Trial Meta-Analysis. International Wound Journal. 2026;23(10):e71058. doi: 10.1111/iwj.71058. PMID: 42820316.
#ActAgainstAmputation #DiabeticFoot #WoundHealing #CAMPs #LimbPreservation
Leave a Reply